Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRX Pharmaceuticals Inc (NRXP) provides investors and healthcare professionals with critical updates on novel therapies for central nervous system disorders and pulmonary diseases. This page aggregates official press releases, clinical trial developments, and regulatory milestones related to the company’s NMDA platform and ketamine-based treatments.
Visitors gain access to verified information about NRX-100 and NRX-101 – investigational therapies targeting suicidal depression and bipolar disorder – along with strategic initiatives through subsidiary HOPE Therapeutics. The resource prioritizes clarity in explaining complex biopharmaceutical concepts while maintaining scientific precision.
Key content includes updates on Fast Track designations, New Drug Application progress, and innovations in preservative-free drug formulations. The curated news collection serves as a decision-making tool for tracking the company’s progress in addressing unmet medical needs through rigorous clinical research.
Bookmark this page for streamlined access to NRX Pharmaceuticals’ latest developments in interventional psychiatry and small-molecule therapeutics. Check regularly for authoritative updates on pipeline advancements and regulatory strategy execution.
NRx Pharmaceuticals (NASDAQ:NRXP) announced that its wholly-owned subsidiary, HOPE Therapeutics, has signed a binding Letter of Intent to acquire a majority stake in Neurospa TMS Holdings, which operates six interventional psychiatry clinics on Florida's Gulf Coast.
Neurospa, which is currently revenue-generating and EBITDA positive, provides comprehensive psychiatric care including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Spravato® treatments, along with traditional psychiatry and talk therapy. These services target patients with depression, suicidality, PTSD, anxiety, and related disorders.
The acquisition is expected to be accretive to HOPE's revenue projections for 2025. The deal completion is contingent on financial audits, definitive agreements, and standard closing conditions.
NRx Pharmaceuticals (NASDAQ:NRXP) reported significant developments in Q4 2024 and FY2024. The company initiated NDA filings for two key products: NRX-100 (IV Ketamine) for Suicidal Depression and NRX-101 for bipolar depression, both with anticipated PDUFA dates before December 31, 2025.
Key financial highlights include:
- Reduced operating loss by 33.5% to $18.5M in 2024 from $27.8M in 2023
- R&D expenses decreased by 53.6% to $6.2M
- G&A expenses reduced to $13.5M from $14.2M
- Cash position of $1.4M as of December 31, 2024, with additional $8.5M raised in January 2025
Strategic developments include:
- Received non-binding terms for NRX-100 licensing worth over $300M in milestones plus double-digit royalties
- HOPE Therapeutics signed LOIs to acquire three precision psychiatry centers
- Regained NASDAQ compliance
- Management forecasts profitability by year-end 2025
NRx Pharmaceuticals (NRXP) has announced it will release its fourth quarter and full year 2024 financial results before market opening on March 17, 2025. The clinical-stage biopharmaceutical company will follow the release with a conference call and corporate update at 8:30am ET.
The financial results will be accessible via press release on the company's investor relations website. Interested parties can join the conference call through a live webcast or by telephone, with domestic callers using +1-800-717-1738 and international callers using +1-646-307-1865.
NRx Pharmaceuticals (NASDAQ:NRXP) and its wholly-owned subsidiary HOPE Therapeutics have announced their participation in two major healthcare conferences in February 2025. The company's Founder, Chairman and CEO, Dr. Jonathan Javitt, will present a company update at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025, from 9:20 to 9:50 AM EST.
The presentation will be available through a live webcast on the NRX Events section of the company's Investor Relations website, with replay access for 30 days post-event. Additionally, management will attend the 2025 BIO CEO & Investor Conference and will be available for one-on-one meetings in New York from February 10th-12th, 2025.
HOPE Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), has engaged BTIG as its financial advisor to support its expansion plans. BTIG will assist in evaluating strategic and financing options, identifying potential acquisition targets, and structuring equity and debt financing for HOPE's planned network of interventional psychiatry clinics.
The company recently secured a $27 million funding agreement for HOPE Clinic Acquisition and plans to leverage this investment with proposed bank debt to fund its initial rollup of Interventional Psychiatry Clinics. These facilities will combine ketamine treatment with transcranial magnetic stimulation and digital therapeutics to treat severe depression and PTSD.
HOPE Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), has secured a $27 million funding transaction with Smith & Sauer, The agreement includes an immediate $2 million investment in NRx common stock and a commitment for $25 million in HOPE's Series A Preferred Stock, with $6.75 million due by February 7, 2025, and the remaining $18.25 million by April 1, 2025.
The funding will support HOPE's strategy to acquire Interventional Psychiatry Clinics, starting with Kadima Neuropsychiatry in La Jolla, CA. The company aims to achieve approximately $100 million in pro-forma revenues by end-2025 through these acquisitions. HOPE plans to establish a nationwide chain of facilities combining ketamine and psychedelic medications with Transcranial Magnetic Stimulation and FDA-approved Digital Therapeutics, focusing on treating severe depression, PTSD, and related disorders.
NRx Pharmaceuticals (NASDAQ:NRXP) has secured $8.9 million in financing through a combination of equity and debt arrangements with Anson Funds. The deal includes $3.5 million in above-market equity through a registered direct offering of common stock at $2.88 per share, and $5.4 million in senior secured convertible notes with a 15-month term.
The company will issue approximately 1.2 million shares and an equal number of warrants exercisable at $2.88 per share. The notes, issued at an 8% discount with 6% annual interest, will be initially convertible at $3.78 per share.
The funding is expected to support NRX-100 (ketamine) and NRX-101 New Drug Applications, launch HOPE Therapeutics, and potentially fund operations into 2026. The company aims to reach profitability through projected product sales and potential non-dilutive funding.
NRx Pharmaceuticals (NASDAQ: NRXP) has successfully regained compliance with Nasdaq's minimum market value of listed securities (MVLS) requirement. The company received written confirmation from Nasdaq Listing Qualifications Staff on January 17, 2025, stating that the compliance issue has been resolved.
The company had previously been notified of non-compliance on August 6, 2024, for failing to maintain an MVLS of at least $35 million over 30 consecutive trading days. To regain compliance, NRXP needed to maintain an MVLS of at least $35 million for a minimum of 10 consecutive trading days, which was achieved on January 16, 2025.
NRx Pharmaceuticals (NASDAQ:NRXP) has announced key appointments to its Board of Directors. Michael Taylor, with over 25 years of experience in global credit markets, joins as a Board Member and Board Designee of Smith & Sauer, following their recent financing. Taylor's extensive background includes roles as Partner at Adi Dassler International Family Office and Managing Director at Oppenheimer & Co.
Anita Nunes, CEO and Co-Founder of Smith & Sauer, joins as Board Observer and will be appointed to the Board of Directors of HOPE Therapeutics, a wholly owned subsidiary of NRx. Nunes brings over 20 years of experience in transformative growth and has led Smith and Sauer's recent $27 million investment in Hope Therapeutics and NRx Pharmaceuticals. Her background spans artificial intelligence, healthcare, and strategic consulting, with experience at companies like McKesson and Gilead.
NRx Pharmaceuticals (NASDAQ:NRXP) and its subsidiary HOPE Therapeutics announced that Dr. David Feifel, founder of Kadima Neuropsychiatry Institute, was featured on CNN's program "'Special K': The Science & Stigma of Ketamine" hosted by Dr. Sanjay Gupta. Kadima is identified as HOPE's planned flagship clinic acquisition, pending completion of financial audits and standard closing conditions.
Dr. Feifel, who is set to become HOPE's Chief Medical Innovation Officer following the planned acquisition, advocated for ketamine use in appropriate patients under proper psychiatric supervision in a controlled setting. This follows his previous appearance on Dr. Gupta's program "The Wild West of Ketamine Treatment" in August. Dr. Feifel emphasized the importance of providing access to psychiatric centers of excellence for depression treatment using ketamine and other advanced therapies under high medical care standards.
FAQ
What is the current stock price of Nrx Pharmaceuticals (NRXP)?
What is the market cap of Nrx Pharmaceuticals (NRXP)?
